About Envisagenics
Envisagenics is a Healthcare company based in Long Island City (United States) founded in 2014 by Martin Akerman and Maria Luisa Pineda. RNA splicing therapeutics are discovered and developed through AI-driven biotechnology. Envisagenics has raised $46.78 million across 9 funding rounds from investors including New York State, HHS and Bristol-Myers Squibb. Its chief executive, as recorded, is Maria Luisa Pineda. Envisagenics offers products and services including SpliceCore and SpliceIO. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Technology Platforms. Its competitors include Seven Bridges Genomics, Dicerna Pharmaceuticals and Ingenuity Systems; 3 of its 3 listed competitors have raised funding.
Company details
Envisagenics was founded in 2014 and is based in Long Island City, United States. Operations center on the biotechnology sector, where novel RNA splicing therapeutics are discovered and developed using artificial intelligence. A cloud-based platform called SpliceCore is provided, which has been experimentally validated to predict drug targets and biomarkers via splicing analysis of RNA-seq data.
- Headquarters Long Island City, United States
- Founders Martin Akerman, Maria Luisa Pineda
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website envisagenics.com
- Social LinkedIn X Facebook YouTube
- Total Equity Funding$46.78M (USD)
in 9 rounds
- Latest Funding Round$25M (USD), Series B
Jun 2024
- InvestorsNew York State
& 15 more
Products & Services of Envisagenics
Envisagenics offers a comprehensive portfolio of products and services, including SpliceCore and SpliceIO.
AI tool for discovering RNA splicing drug targets
Identifies tumor-specific neoepitopes for therapies
Apps and channels of Envisagenics
its YouTube channel Envisagenics has 29 subscribers and 7 videos.
Videos from Envisagenics
The most watched videos on Envisagenics's YouTube channel, Envisagenics (29 subscribers). Click a video to play it here.
More on Envisagenics.
Funding Insights of Envisagenics
Envisagenics has successfully raised a total of $46.78M across 9 strategic funding rounds. The most recent funding activity was a Series B round of $25 million completed in June 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $46.78M
- Total Rounds 9
- Last Round Series B — $25M
- First Round $100,000
(Jul 2015)
- Investors Count 16
All 9 funding rounds of Envisagenics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2024 | $25M | Series B | – | Third Kind Venture Capital, New York State | – |
| Jul 2022 | $2.08M | Grant | – | – | |
| Sep 2021 | $19.18M | Series A | – | Red Cell Partners | |
| Oct 2019 | $300,000 | Grant | – | – | |
| Sep 2019 | $301,502 | Grant | – | – | |
| Mar 2017 | $2.5M | Seed | – | Dynamk Capital | |
| Jun 2016 | Seed | – | – | ||
| Aug 2015 | $1.85M | Grant | – | – | |
| Jul 2015 | $100,000 | Seed | – | – |
16 investors in total: 16 institutional.
Investors in Envisagenics
Envisagenics has secured backing from 16 investors, including institutional and venture fund investors. Prominent investors backing the company include New York State, HHS and Bristol-Myers Squibb.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Technology companies are incubated by Red Cell Partners for critical sectors. | 2020 | redcellpartners.com | ||
Venture capital investments in technology startups are facilitated by M12. | m12.vc | San Francisco, United States | ||
Venture capital investing in AI, biotech, and technology sectors, focusing on seed and early stages in Seattle and beyond. | madrona.com | |||
Early-stage investments in finance and financial services are targeted. | 3kvc.com | New York, United States | ||
Investment in life sciences innovation is facilitated by Dynamk Capital. | dynamk.vc | New York, United States | ||
Venture capital fund focused on early-stage biotech, life sciences, IT, and multiple sectors | dolbyventures.com | San Francisco, United States | ||
Empire State Development is focused on economic growth in New York. | esd.ny.gov | New York, United States | ||
Early-stage investments are provided to transformative technology companies. | svangel.com | San Francisco, United States | ||
Accelerate Long Island is focused on fostering tech and science-driven startups. | accelerateli.org | Melville, United States | ||
Topspin Consumer Partners is engaged in private equity investments focused on consumer brands. | topspincp.com | Mamaroneck, USA |
Investor details for Envisagenics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Envisagenics
23 people are tracked at Envisagenics (9 in leadership, 4 in board & advisors, 10 in team).
| Name | Role | Group |
|---|---|---|
Martin Akerman | Co-Founder & CTO | Leadership |
Maria Luisa Pineda | Co-Founder & CEO | Leadership |
Tiffany Tsui | Director of Operations | Leadership |
Sudhir Rao | Chief Business Officer | Leadership |
Bradley Harris | Chief Operating Officer and General Counsel | Leadership |
Gayatri Arun | Executive Vice President Of Biology | Leadership |
Alyssa Fronk, Ph.D. | Director Of Computational Biology | Leadership |
Miguel A. Manzanares | Director Of Oncology Programs | Leadership |
Kendall Anderson | Director Of Target Discovery | Leadership |
Sudhir Agrawal | Scientific Advisor | Board & advisors |
Omar I. Abdel-Wahab | Scientific Advisor | Board & advisors |
Michael Q Zhang | Scientific Advisor | Board & advisors |
Michael Grissinger | Business Advisor | Board & advisors |
Hasan Ekrem Zumrut | Research Scientist | Team |
Matthew Hamlyn | Operations & Marketing Coordinator | Team |
Sakshi Gera | Senior Research Scientist | Team |
Anushka Bhargava | Research Scientist | Team |
George Devon Trahan | Senior Bioinformatics Engineer | Team |
Jonathan Abebe | Bioinformatics Scientist | Team |
Brian Jurgielewicz | Research Scientist | Team |
3 more people are available in the full profile.
Complete people profiles for Envisagenics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Envisagenics
3 dated milestones of Envisagenics across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Envisagenics is founded.
- Funding First funding round of $100K.
- Funding Latest funding round, Series B, of $25.0M.
Competitors of Envisagenics
Envisagenics has 3 listed competitors in our database, 3 of them funded. They include Seven Bridges Genomics, Dicerna Pharmaceuticals and Ingenuity Systems.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sevenbridges.com | 2009 | Cambridge, United States | $113M | 112 | Cloud-based platform to analyze, store, and act on genomic data. | |
| dicerna.com | 2007 | Lexington, United States | $106.45M | 337 | Drugs are developed using RNA interference technology platform. | |
| ingenuity.com | 1998 | Redwood, United States | $20.4M | 30 | Genomic data is analyzed and interpreted via web-based applications. |
Detailed competitors of Envisagenics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Envisagenics
- Global rank#7,646,698
among all websites
- Category rank#7,100
Health · Biotechnology and Pharmaceuticals
- Bounce rate31%
- Pages per visit2.4
- Average visit32 sec
- DevicesDesktop 59% · Mobile 41%
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Envisagenics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Envisagenics
Complete news archive for Envisagenics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Envisagenics
Envisagenics was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Envisagenics is headquartered in Long Island City, United States. It is registered at Long Island City, New York, United States.
Maria Luisa Pineda is the CEO of Envisagenics, as recorded in our data. They have also founded this company.
Envisagenics is a funded company, having raised a total of $46.78M across 9 funding rounds to date. The company's 1st funding round was a Seed of $100K, raised on Jul 2015.
Envisagenics was founded in 2014 and is based in Long Island City, United States. Operations center on the biotechnology sector, where novel RNA splicing therapeutics are discovered and developed using artificial intelligence. A cloud-based platform called SpliceCore is provided, which has been experimentally validated to predict drug targets and biomarkers via splicing analysis of RNA-seq data.
Envisagenics's top competitors include Dicerna Pharmaceuticals, Ingenuity Systems and Seven Bridges Genomics.
Envisagenics offers SpliceCore and SpliceIO.
Envisagenics has 16 investors. Key investors include New York State, HHS, Bristol-Myers Squibb, National Cancer Institute, and Red Cell Partners.